Legendary Guitarist Campbell In Remission Again From Hodgkin's

In what has become a see-saw battle, guitarist Vivian Campbell is reporting that his Hodgkin's lymphoma has once again been put into remission.

The Def Leppard guitarist first reported that he had been diagnosed with Hodgkin's lymphoma back in June of 2013.

Five months later, fans learned that doctors declared the legendary guitarist to be in remission from the disease.

Six months after that, Campbell revealed that his Hodgkin's had returned and that he would undergo additional treatment.

Less than three months later, Campbell is now reporting on his Facebook page that, although still undergoing treatments, he has once again been told he is in remission:

For those of you that give a toss, here’s the latest and greatest on my cancer situation. I’m currently in Boston and I did a scan on Tuesday morning. The scan shows that the cancer is in remission. Great news, but I’m trying not to get too excited about it as I heard that same phrase late last year only to be disappointed again a few months after when it returned. The plan is to do a stem cell transplant as soon as the tour is finished. However, to keep me in remission my doctors have recommended that I do another, 3rd, round of the chemo (I.C.E.), so I’m back in hospital, all hooked up and doing my rock n’ roll drugs…

Source: Facebook

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap